Veradermics is a promising new treatment for hair loss, essentially a repackaged version of Minoxidil. The user is optimistic about its potential effectiveness.
Hair loss is causing distress and self-esteem issues, with discussions on treatments like finasteride, minoxidil, and hair transplants. Some suggest topical treatments or lifestyle changes, while others stress the importance of confidence and self-acceptance.
The conversation discusses the lack of updates on GT20029 for hair loss treatment, with some users noting recent reports indicating ongoing data collection. There are mentions of other treatments like Pyrilutamide and Minoxidil.
A user shared their 3-month progress using RU58841, 10% minoxidil, and microneedling every two weeks for hair loss. They found the new minoxidil sprayer effective for applying the treatment across the scalp.
The conversation confirms that to make a 5% RU58841 solution, 1.5 grams should be added to 30 mL of KB Solution. The discussion involves calculating the correct dosage for hair loss treatment.
Hair loss concerns and treatments like Minoxidil and Finasteride are humorously discussed. The community's quirks and dedication to battling hair loss are highlighted.
The user has been using a regimen of topical Minoxidil and Finasteride, oral Minoxidil, topical tretinoin, dutasteride once a week, and microneedling weekly for two years with no progress. Suggestions include taking dutasteride daily instead of weekly.
The user tried Redensyl but stopped using topical finasteride and continued with 5% minoxidil. They are experiencing hair loss and considering accepting baldness.
A user found a successful hair loss treatment using a combination of finasteride, dutasteride, minoxidil, and RU58841. They plan to switch to a purely topical regimen with finasteride, RU58841, and minoxidil.
The conversation discusses using RU58841, Minoxidil, and finasteride for hair loss treatment. It focuses on homebrewing RU58841 while using other treatments.
A naturally occurring sugar, 2-deoxy-D-ribose, may promote hair growth by forming new blood vessels. There is skepticism about its effectiveness and concerns about potential side effects, with some users comparing it to existing treatments like Minoxidil and finasteride.
The user has been using finasteride and minoxidil for hair loss but experienced worsening temple recession. They suspect they might be more sensitive to testosterone and are considering trying RU58841 or CB 03 01 as additional treatments.
RU58841 and topical GHK-CU are used together for hair loss, with RU58841 reducing shedding and GHK-CU improving scalp health. Users report noticeable hair growth and improved hair quality within weeks, especially when used consistently.
Users discuss aggressive promotion of Koshine 826, suspecting Kintor employees are behind it. Concerns are raised about its effectiveness, with some preferring alternatives like finasteride and minoxidil.
RU58841 is a strong non-steroidal antiandrogen for hair loss but may cause cardiovascular issues in some users. Alternatives like Pyrilutamide and Breezula are suggested due to better safety profiles and lower systemic risks.
RU58841 was used by some for hair loss, but concerns about side effects like gynecomastia and safety were raised. Alternatives like finasteride, minoxidil, pyrilutamide, and alfatradiol were discussed, with some users reporting better experiences with these treatments.
The post is about using different solutions for RU58841, a treatment for hair loss. The user is asking for opinions on the effectiveness of different vehicles and dosages.
21-year-old female experiencing hair loss and visible scalp seeks advice on PRP effectiveness. Currently taking spironolactone and krimson for high androgens, unsure if PRP can be done with these medications.
Cyclosporine A is discussed as a powerful hair growth stimulant, potentially more effective than minoxidil, but concerns about safety and side effects, including cancer risk, limit its use. The conversation highlights the need for further research and experimentation with topical application, despite its risks.
GT20029 showed promising results for hair growth in a Phase II trial, with the 1.0% twice-weekly regimen being the most effective. Some users expressed skepticism and humor about the product's effects and market availability.
Rosemary oil is compared to minoxidil 2%, but its effectiveness and safety are questioned. Minoxidil 5% is considered safer and more reliable for hair loss prevention.
Clascoterone, an acne treatment that blocks DHT, is being developed for scalp use against hair loss. The conversation also mentions Minoxidil, finasteride, and RU58841 as treatments.
The conversation is about finding a reliable source for CB 03-01 as an alternative treatment for hair loss due to intolerance to finasteride and RU58841. The user is also considering minoxidil for temporary effectiveness.
The conversation discusses experiences with Haircross Hair Growth Serum, which contains Redensyl, Capixyl, Procapil, Anagain, and Baicapil, as an alternative to Minoxidil and Finasteride. Users report mixed results, with some experiencing no regrowth and others noting slight thickening, but concerns about side effects and effectiveness compared to standard treatments remain.
ET-02 showed significant hair growth in five weeks, outperforming minoxidil, with a non-hormonal mechanism that avoids side effects of treatments like finasteride. A phase 2 trial is planned to further assess ET-02's efficacy and safety.
Ursolic acid, found in apple peels, lemongrass, rosemary, and lavender, may have anti-androgen effects similar to finasteride. It might be beneficial for hair health when used with other treatments like Minoxidil, Finasteride, and RU58841.
The conversation is about using Winlevi Clascoterone cream for hair loss. The user is considering adding it to their routine, which includes a topical hair growth serum, and is seeking feedback on its effectiveness.
The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.